Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Mesothelioma: HELP
Articles by Tsunekazu Hishima
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Tsunekazu Hishima wrote the following 2 articles about Mesothelioma.
 
+ Citations + Abstracts
1 Review Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review. 2016

Hashimoto, Kana / Okuma, Yusuke / Hosomi, Yukio / Hishima, Tsunekazu. ·Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan. · Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan. y-okuma@cick.jp. · Division of Oncology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan. y-okuma@cick.jp. · Department of Pathology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan. ·BMC Cancer · Pubmed #27599565.

ABSTRACT: BACKGROUND: Desmoplastic malignant pleural mesothelioma (DMM) is rare histological subtype of diffuse malignant pleural mesothelioma (MPM), accounting for 5-10 % of cases. It has a poor prognosis, with direct invasion of the chest wall or lungs and distant metastases. Its pathological characteristics include dense collagen fibers in a storiform pattern. Its pretreatment pathological diagnosis is difficult, with fibrous pleuritis and reactive mesothelial hyperplasia as potential differential diagnoses. CASE PRESENTATION: We retrospectively reviewed the medical charts of patients with MPM from 1996 to 2012. Among 60 patients with MPM, four patients with the desmoplastic subtype were identified and their clinical characteristics, including asbestos exposure, treatment, and prognosis, were reviewed. All of the patients with DMM were men, with a median age of 69 years (range: 63-74 years). All four patients had been exposed to asbestos. The definitive diagnosis was made histologically and the International Mesothelioma Interest Group classification was advanced (III/IV: 2/3) in all four patients. Three patients were treated with chemotherapy (two with cisplatin/pemetrexed and one with cisplatin/gemcitabine) and one patient underwent surgery. The median survival time in the patients with DMM was 3.8 months (range: 0.9-11.5 months), compared with 10.5 months in patients with other subtypes of MPM in our institution. CONCLUSIONS: DMM continues to have a poor prognosis. It is important to recognize this variant and distinguish it from pleural plaques, non-specific reactive pleural fibrosis, pleurisy, and other lung diseases.

2 Article Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis. 2016

Ebata, Takahiro / Okuma, Yusuke / Nakahara, Yoshiro / Yomota, Makiko / Takagi, Yusuke / Hosomi, Yukio / Asami, Eichi / Omuro, Yasushi / Hishima, Tsunekazu / Okamura, Tatsuru / Takiguchi, Yuichi. ·Department of Thoracic Oncology and Respiratory Medicine Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Bunkyo Japan; Department of Medical Oncology, Graduate School of Medicine Chiba University Chiba Japan. · Department of Thoracic Oncology and Respiratory Medicine Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Bunkyo Japan. · Department of Pathology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Bunkyo Japan. · Department of Chemotherapy Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Bunkyo Japan. · Department of Medical Oncology, Graduate School of Medicine Chiba University Chiba Japan. ·Thorac Cancer · Pubmed #26816537.

ABSTRACT: BACKGROUND: Malignant pleural effusion (MPE) can occur during the progression of various cancers. However, factors, such as the incidence of MPE associated with different types of cancers and its potential for diagnosing previously undetected cancers, are unknown. Moreover, MPE may accompany potentially curable cancers or those with a favorable survival prognosis with adequate treatment. The present study determined the types of cancers accompanied by MPE at initial diagnosis and investigated appropriate related methods for diagnosing previously unknown cancers. METHODS: We retrospectively reviewed the medical records of 35 patients with MPE at initial cancer diagnosis between 2004 and 2012. We evaluated the patient characteristics, final diagnosis, and diagnostic processes. RESULTS: Of the 35 patients, 10 had lung cancer, seven ovarian or peritoneal cancer, four malignant pleural mesothelioma, one breast cancer, one lymphoma, one pancreatic cancer, and 11 had cancers of unknown origin. Diagnoses of the primary lesions were confirmed using the MPE cellblock method for seven of 11 patients (63.6%), by excisional biopsy or aspiration from other sites in four of nine patients, by exploratory laparotomy in two of three patients, and by peritoneal washing cytology in five patients. CONCLUSION: Lung cancer and cancer of unknown origin are major causes of MPE at initial presentation. However, these groups also contain cancers that are curable and those with good long-term prognosis. The MPE cellblock method represents an accurate method for identifying cancer origin.